Finlay Vaccine Institute and University of Uruguay Sign Memorandum of Understanding at VacciPharma2023
The Finlay Vaccine Institute and the Department of Biotechnological Development of the University of Uruguay have signed a Memorandum of Understanding (MoU) during the international event VacciPharma2023. The aim of the MoU is to promote cooperation between the two institutions in the field of vaccine research and development.
The signing ceremony took place at VacciPharma2023 and was attended by Dr. Vicente Vérez Bencomo, director of the Finlay Vaccine Institute, and José A. Chabalgoity, director of the Department of Biotechnological Development of the University of Uruguay. The agreement plans to carry out extensive joint work related to vaccine research and development.
VacciPharma2023, held every two years in Cuba, serves as a platform for Cuban and foreign delegates to present research results, developments, quality control strategies, and technological elements in vaccine production. This year, specialists from Saudi Arabia, the United States, Uruguay, Argentina, the United Kingdom, Germany, Spain, Russia, Switzerland, Italy, India, Nicaragua, and Cuba gathered to share experiences and knowledge during the four-day event.
The event is organized by the Cuban Society of Pharmacology and BioCubaFarma companies. Due to the Covid-19 pandemic, the last two editions of VacciPharma were not held, making this year’s event particularly relevant for Cuban science as it allowed the resumption of scientific and academic exchange.
The signing of the MoU between the Finlay Vaccine Institute and the University of Uruguay marks a significant step towards international collaboration in vaccine research and development. Both institutions are committed to advancing the field and contributing to global efforts in combating diseases through innovative vaccine solutions.
(With information from the Finlay Vaccine Institute)
How does the partnership between the Finlay Vaccine Institute and the University of Uruguay contribute to global health efforts in vaccine research and development
The Finlay Vaccine Institute and the Department of Biotechnological Development of the University of Uruguay have come together in an exciting partnership. Recently, during the renowned international event VacciPharma2023, these two prestigious institutions signed a Memorandum of Understanding (MoU). The purpose of this MoU is to foster collaboration and cooperation in the crucial field of vaccine research and development.
The signing ceremony itself was a momentous occasion, taking place at VacciPharma2023 and graced by the presence of esteemed figures in the field. Dr. Vicente Vérez Bencomo, director of the Finlay Vaccine Institute, and José A. Chabalgoity, director of the Department of Biotechnological Development of the University of Uruguay, were among the key individuals in attendance. Together, they reaffirmed their commitment to working together on a wide range of projects related to vaccine research and development.
VacciPharma2023 serves as an important platform for scientists and experts from various nations to share their latest findings, advancements, quality control strategies, and technological breakthroughs in vaccine production. The event, which takes place every two years in Cuba, attracts professionals from all over the world. This year, representatives from Saudi Arabia, the United States, Uruguay, Argentina, the United Kingdom, Germany, Spain, Russia, Switzerland, Italy, India, Nicaragua, and of course, Cuba, gathered for four days of meaningful exchange and collaboration.
To ensure the success of VacciPharma2023, the Cuban Society of Pharmacology and BioCubaFarma companies joined forces to organize the event. Given the disruptions caused by the Covid-19 pandemic, the previous two editions of VacciPharma had to be canceled. Thus, this year’s gathering held even greater significance for the scientific community, as it marked the resumption of vital scientific and academic exchange.
The signing of the MoU between the Finlay Vaccine Institute and the University of Uruguay is an extraordinary leap forward in international collaboration within the field of vaccine research and development. Both institutions possess unparalleled expertise and are fully dedicated to advancing the field and contributing to global health efforts by developing innovative vaccine solutions.
With this exciting partnership established, we can look forward to groundbreaking collaborations and significant advancements that will benefit humanity in the ongoing fight against diseases. The Finlay Vaccine Institute and the University of Uruguay are leading the charge in forging new paths to a healthier world through their unwavering commitment to scientific excellence and innovation.
(With information from the Finlay Vaccine Institute)
This collaborative step between the Finlay Vaccine Institute and University of Uruguay marks a promising future for vaccine research and development. Exciting times ahead at VacciPharma2023!